Print

Purpose

The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Aged ≥18 years at index date. - Have a confirmed diagnosis of schizophrenia before index date. - Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy. - Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines. - Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish). - English or Spanish speaking.

Exclusion Criteria

  • Participation in an interventional study within the last 30 days or plan to participate in such study at the time of eligibility screening. - Evidence of use of XT prior to time of eligibility screening.

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Participants receiving xanomeline and trospium chloride (X/T) therapy
  • Drug: xanomeline and trospium chloride (X/T) therapy
    According to the product label

Recruiting Locations

Lumos Clinical Research Center
San Jose, California 95124
Contact:
Sarbani Maitra, Site 0010
408-668-2712

Evanston Hospital
Evanston, Illinois 60201
Contact:
Joshua Straus, Site 0003
312-399-3795

The Johns Hopkins Hospital
Baltimore, Maryland 21287
Contact:
Frederick Nucifora, Site 0007
215-620-3793

Boston Medical Center
Boston, Massachusetts 02118
Contact:
Hannah Brown, Site 0002
617-638-8141

Mayflower Clinical
South Dartmouth, Massachusetts 02747
Contact:
Simon Desjardins, Site 0011

Omaha Insomnia and Psychiatric Services
Omaha, Nebraska 68144
Contact:
Vithya Selvaraj, Site 0005
402-991-9630

Hackensack Meridian Health - Carrier Clinic
Belle Mead, New Jersey 08502
Contact:
Stacy Doumas, Site 0001

Radial - Manhattan
New York, New York 10018
Contact:
Owen Muir, Site 0015
929-260-5003

New Dawn Psychiatric Services, PLLC
Kinston, North Carolina 28501
Contact:
Punitha Rathnam, Site 0016
252-686-8091

New Dimension Group
Rose Hill, North Carolina 28458
Contact:
Constance Olatidoye, Site 0018
910-233-2813

Westlake Brain Health
Westlake, Ohio 44145
Contact:
Abdelrahman Abdelaziz, Site 0014
317-560-2391

Continuum Health Providers
Fort Mill, South Carolina 29708
Contact:
Brian Mika, Site 0006

Haracec Clinical Research
El Paso, Texas 79902
Contact:
Aghaegbulam Uga, Site 0012

C-Trilogy Outreach
Longview, Texas 75601
Contact:
Tracy Hicks, Site 0013
903-576-2629

More Details

Status
Recruiting
Sponsor
Bristol-Myers Squibb

Study Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
Clinical.Trials@bms.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.